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Abstract
The repair of DNA double-strand breaks (DSBs) is the major mechanism to maintain genomic stability in response to
irradiation. We hypothesized that genetic polymorphisms in DSB repair genes may affect clinical outcomes among non-
small cell lung cancer (NSCLC) patients treated with definitive radio(chemo)therapy. We genotyped six potentially functional
single nucleotide polymorphisms (SNPs) (i.e., RAD51 2135G.C/rs1801320 and 2172G.T/rs1801321, XRCC2 4234G.C/
rs3218384 and R188H/rs3218536 G.A, XRCC3 T241M/rs861539 and NBN E185Q/rs1805794) and estimated their associations
with overall survival (OS) and radiation pneumonitis (RP) in 228 NSCLC patients. We found a predictive role of RAD51
2135G.C SNP in RP development (adjusted hazard ratio [HR]=0.52, 95% confidence interval [CI], 0.31–0.86, P=0.010 for
CG/CC vs. GG). We also found that RAD51 2135G.C and XRCC2 R188H SNPs were independent prognostic factors for
overall survival (adjusted HR=1.70, 95% CI, 1.14–2.62, P=0.009 for CG/CC vs. GG; and adjusted HR=1.70; 95% CI, 1.02–2.85,
P=0.043 for AG vs. GG, respectively) and that the SNP-survival association was most pronounced in the presence of RP. Our
study suggests that HR genetic polymorphisms, particularly RAD51 2135G.C, may influence overall survival and radiation
pneumonitis in NSCLC patients treated with definitive radio(chemo)therapy. Large studies are needed to confirm our
findings.
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Introduction
Lung cancer leads all other cancers in both incidence and
mortality worldwide. Non-small cell lung cancer (NSCLC) accounts
for 89% of all lung cancer, and most patients have advanced stages
at diagnosis, requiring radiotherapy alone or in combination with
chemotherapy to improve the local control and overall survival.
However, despite aggressive treatment in these patients, the
prognosis is still unsatisfactory, with a 5-year survival rate of about
10% [1] and a median survival time (MST) of 16–18 months [2].
Meanwhile, radiation treatment-related pulmonary toxicity, such as
pneumonitis and pulmonary fibrosis, may influence the prognosis of
NSCLC patients, because these complications restrict the dose of
radiation used and compromise pulmonary functions. Therefore,
there has been a persistent interest in search for readily accessible
molecular markers that may help assess therapeutic benefits by
predicting clinical outcomes of those NSCLC patients who are
treated with definitive radio(chemo)therapy.
The DNA double-strand breaks (DSBs) are the principle
genotoxic lesions of ionizing radiation, which pose major threats
to genomic integrity. It is estimated that a dose of ,1 Gy of X-rays
produces about 50–100 double-strand breaks in the DNA of a
typical mammalian cell, leading to 50% cell death [3,4]. There are
two main pathways for DNA DSB repair—homologous recom-
bination (HR) and non-homologous end-joining (NHEJ). In HR,
the initial step involves recognition and signaling of DSB by a
protein complex of NBN, MRE11 and RAD50; then RAD51
protein is recruited to catalyze the strand exchange reaction and
some RAD51-related proteins, such as RAD51 B-D, XRCC2 and
XRCC3, participate in the assembly of the RAD51 nucleoprotein
filament and the selection and interaction with the appropriate
recombination substrates [5].
There is a genetic basis of cellular responses to ionizing radiation
in cancer treatment, because patients receiving similar treatment
could have different response to radiotherapy. Previous studies
demonstrated that elevated expression of some DSB repair proteins,
such as RAD51, NBN and XRCC3, confers radioresistance [6,7,8],
whereas loss of XRCC2 results in a severe delay in the early
response of DSB [9]. Patients of a rare congenital disorder,
Nijmegen breakage syndrome, are extremely sensitive to radiation
because of a compromised DSB repair capacity due to NBN
mutations [10]. Hence, it is reasonable to speculate that the inter-
individual variability in DSB repair capacity may modulate
phenotype of radiosensitivity and clinical outcomes of radiotherapy.
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function or can be used as genetic markers to detect nearby disease-
causing variants through association or linkage studies, we sought to
evaluate the association of six potentially functional SNPs (i.e.,
RAD51 2135G.C/rs1801320, 2172G.T/rs1801321, XRCC2
4234G.C/rs3218384, R188H/rs3218536 G.A, XRCC3 T241M/
rs861539, and NBN E185Q/rs1805794) of genes involved in HR
pathway with radiation pneumonitis (RP) and overall survival (OS)
of NSCLC patients treated with definitive radio(chemo)therapy in
the present study.
Materials and Methods
Ethics statement
This study was approved by The University of Texas M. D.
Anderson Cancer Center Institutional Review Board and
informed consents were waived. We complied with HIPAA
regulations.
Study populations
In the study, clinical data were derived from a dataset of 261
patients with histopathologically confirmed NSCLC, who were
treated with definitive radiation at our institution between 1999
and 2005. Among these 261 patients, 231 patients had
documented survival information. After we excluded those
patients who had surgical resection or recurrence before
radiotherapy, the final data pool consisted of 228 patients with
stage IA to IV NSCLC and survival information and 196 patients
with pneumonitis information and radiation dosimetric data. The
details of the radiation treatment planning, follow-up schedule and
tests, and dosimetric data analysis were described in our previous
publication [11].
Selection of SNPs and genotyping
We selected six common (minor allele frequency .0.05 in
Caucasians), well-studied functional variants of RAD51, XRCC2,
XRCC3 and NBN genes involved in HR pathway: RAD51
2135G.C/rs1801320, 2172G.T/rs1801321, XRCC2 4234G.
C/rs3218384, R188H/rs3218536 G.A, XRCC3 T241M/
rs861539 and NBN E185Q/rs1805794. This is because they are
located in promoter region or cause nonsynonymous amino acid
changes that have been reportedly associated with cancer risk or
survival. Although MRE11 and RAD50 genes are also important in
the initial stage of response to DSB, no functional SNPs have been
reported so far and therefore, these two genes were not included in
our study. Genomic DNA was extracted from the buffy coat
fraction of each blood sample by using a Blood Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. DNA
purity and concentrations were determined by spectrophotometric
measurement of absorbance at 260 and 280 nm by a UV
spectrophotometer (Nano Drop Technologies, Inc., Wilmington,
DE). Genotypes were generated by the polymerase chain reaction
(PCR)-restriction fragment length polymorphism (RFLP) method
(Figure S1). The primer sequences, restriction enzymes and PCR
conditions used for the experiments were available upon request.
Selection of end points
We selected overall survival and occurrence of radiation
pneumonitis as our study end points. There are five grades of
radiation-treatment related pneumonitis according to the Com-
mon Terminology Criteria for Adverse Events version 3.0 [12].
Previous studies have used two different types of criterion in RP
investigation: RP of any grade (grade$1) [13,14,15] and RP
requiring clinical intervention (grade$2 or 3) [16,17]. In this
study, we used RP of any grade (grade$1) to include more RP
events. All times to the endpoints were calculated from the first day
of radiation treatment until the date of event or the last known
follow-up.
Statistical methods
The hazard ratios (HRs) with their corresponding 95%
confidence intervals (CIs) were calculated by Cox proportional
hazard analyses to evaluate the influence of various genotypes on
overall survival and radiation pneumonitis. The HRs for OS were
adjusted for age, sex, race, Karnofsky performance scores (KPS),
smoking status, tumor histology, disease stage, application of
chemotherapy and radiation dose; whereas the HRs for RP were
adjusted for age, sex, race, KPS, smoking status, tumor histology,
disease stage, application of chemotherapy and mean lung dose
because mean lung dose is the traditional dosimetric factor to be
associated with RP. Kaplan-Meier analysis was used to evaluate
the effect of different genotypes on the cumulative probability of
overall survival and radiation pneumonitis. All reported P values
were two-sided, and P,0.05 indicates statistical significance. All
analyses were performed using SAS software (version 9.1; SAS
Institute, Cary, NC). The Bonferroni method was used to adjust
for multiple comparisons.
Results
Population characteristics
The 228 patients used for the final analysis included 125 men
and 103 women, with a median age of 63 years (range, 35 to 88
years). Among them, 74.6% were white, 82.5% had stage III/IV
disease, 88.2% were treated with a combination of chemotherapy
and radiotherapy, and 96.8% received radiation doses between 60
and 70 Gy. The median overall survival time was 20 months and
the median time for RP development was 4.3 months. Patient-,
disease-, and treatment-related characteristics and their influences
on OS and RP (grade$1) are shown in Table 1. In the univariate
analysis, we found that male, tumor stage of III/IV, and histology
of ‘‘not otherwise specified’’ were significantly associated with
reduced OS, whereas tumor stage of I/II seemed to be associated
with reduced RP. The most commonly used dosimetric factor of
mean lung dose was only available for the 196 patients who were
treated with 3-dimensional conformal radiation and who had
pneumonitis information and was marginally associated with RP
development in our analysis (Table 1).
Association between overall survival and polymorphisms
The genotype distributions of SNPs in genes involved in the HR
pathway and the association with OS are summarized in Table 2.
Compared with the homozygote RAD51 2135GG genotype, the
CG/CC genotypes were marginally associated with a hazard of
early death in the univariate analysis (HR=1.46, 95% CI, 0.99–
2.14, P=0.056). After a multivariate adjustment for age, sex,
smoking status, tumor histology, KPS, tumor stage, application of
chemotherapy, and radiation dose, the HRs were statistically
significant in both RAD51 2135G.C and XRCC2 R188H SNPs
(CG/CC vs. GG: adjusted HR=1.70; 95% CI, 1.14–2.62,
P=0.009; and AG vs. GG: adjusted HR=1.70; 95% CI, 1.02–
2.85, P=0.043, respectively) (Table 2 and Fig. 1A, 1B).
Association between radiation pneumonitis and
polymorphisms
The distributions of genotypes and their association with RP
(grade$1) are summarized in Table 3. Similar to the data of OS,
only RAD51 2135G.C SNP showed a significant association with
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CI, 0.35–0.90, P=0.017). After a multivariate adjustment, the
significance still remained for RAD51 2135G.C SNP in the
dominant model (CG/CC vs. GG: HR=0.52, 95% CI, 0.31–
0.86, P=0.010). The TT genotype of XRCC3 T241M SNP
showed a marginally protective effect against RP in the additive
model (TT vs. CC: HR=0.63, 95% CI, 0.38–1.04, P=0.069)
(Table 3 and Fig. 1C, 1D).
Modification effects of RP by SNPs of RAD51 2135G.C
and XRCC2 R188H on overall survival
Since RAD51 2135G.C and XRCC2 R188H SNPs were also
independent prognostic factors of overall survival, we then
investigated the modification effect of RP by SNPs on OS. We
found that both RAD51 2135G.C and XRCC2 R188H SNPs
showed remarkable influence on OS only in the presence of RP
(adjusted HR=3.03. 95% CI, 1.69–5.45, P,0.001; and adjusted
HR=2.67. 95% CI, 1.13–6.29, P=0.025, respectively) (Table 4
and Fig. 2). There was no difference in the death hazard between
genotypes if RP was absent.
Bonferroni corrections
Because multiple testing may have been contributed to the
findings in the evaluation of the statistical significance of our
primary results, we also considered adjustment for the associations
with the outcomes. After Bonferroni corrections, only RAD51
2135G.C SNP remained significant for its association with both
OS and RP.
Table 1. Patient demographics and association with clinical outcomes of overall survival (OS) and radiation pneumonitis (RP).
OS (N=228) RP (grade$1, N=196)
Parameter No. (%) HR 95% CI P
{ No. (%) HR 95% CI P
{
Sex
Female 103 (45.2) 1.00 83 (42.4) 1.00
Male 125 (54.8) 1.51 1.08–2.11 0.017 113 (57.6) 1.09 0.78–1.54 0.608
Age (years)
,63 113 (49.6) 1.00 97 (49.5) 1.00
$63 115 (50.4) 1.37 0.96–1.94 0.080 99 (50.5) 1.02 0.73–1. 43 0.900
Race
White 170 (74.6) 1.00 141 (71.9) 1.00
Black 45 (19.7) 0.96 0.60–1.54 0.875 42 (21.4) 1.21 0.81–1.81 0.360
Other 13 (5.7) 1.51 0.73–3.12 0.269 13 (6.7) 1.11 0.54–2.28 0.776
KPS
,80 59 (25.9) 1.00 40 (20.4) 1.00
$80 169 (74.1) 0.71 0.46–1.11 0.133 156 (79.6) 1.02 0.61–1.71 0.934
TNM stage
1
III, IV 188 (82.5) 1.00 167 (85.2) 1.00
I, II 34 (14.9) 0.55 0.32–0.94 0.029 29 (14.8) 0.55 0.33–0.93 0.026
Histology
1
Adenocar 77 (33.8) 1.00 66 (33.7) 1.00
NSCLC, NOS 74 (32.5) 1.56 1.04–2.33 0.032 67 (34.2) 0.99 0.66–1.47 0.949
Squamous cell 70 (30.7) 1.41 0.92–2.14 0.138 63 (32.1) 0.73 0.48–1.12 0. 471
Smoking status
Ever 200 (87.7) 1.00 177 (90.8) 1.00
Never 28 (12.3) 1.07 0.61–1.89 0.798 18 (9.2) 1.36 0.77–2.40 0.292
Chemotherapy
1
No 22 (9.6) 1.00 20 (10.3) 1.00
Yes 201 (88.2) 1.02 0.54–1.91 0.957 175 (89.7) 1.61 0.84–3.07 0.151
Mean lung dose (Gy)
,17.67 57 (29.1) 1.00
$17.67 139 (70.9) 1.40 0.95–2.04 0.087
Radiation dose (Gy)
,63 46 (20.2) 1.00 36 (18.4) 1.00
$63 182 (79.8) 0.79 0.50–1.21 0.272 160 (81.6) 0.73 0.47–1.13 0.154
{P values were calculated by univariate Cox proportional hazards model.
1The numbers for certain variables may not add up to the total number because of the missing information.
NOS: Not otherwise specified; KPS: Karnofsky Performance Score.
doi:10.1371/journal.pone.0020055.t001
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To our knowledge, this is the first study to investigate the
association between clinical outcomes and potentially functional
polymorphisms of genes in the HR pathway in NSCLC patients
treated with radiotherapy, with a reasonable sample size (a total of
228). We provided a strong evidence of the predictive value of
RAD51 2135G.C SNP for RP development. RAD51 2135G.C
and XRCC2 R188H SNPs were also independent prognostic
factors of overall survival, and the SNP-survival association was
most pronounced in the presence of RP.
Lung cancer is a disease resulting from interactions between
genetic and environmental factors, and its progression and
prognosis are also heavily influenced by patient host or
treatment-related factors. Some well-known prognostic factors in
inoperable NSCLC patients, such as being male, old age and
advanced tumor stage [18], were present in the current study.
Although the mean lung dose was marginally associated with RP
development by the criterion of grade$1, it was significantly
associated with grade$3 RP (data not shown), which was
consistent with our previous report [19]. The most important
finding from the current study, however, is the modification effect
Table 2. Univariate and multivariate analyses of different genotypes and OS for NSCLC (N=228).
Genotypes Patient No. Event Crude P* Adjusted P
{
HR 95% CI HR 95% CI
RAD51
(rs1801320 2135G.C)
GG 183 124 1.00 1.00
CG 39 29 1.53 1.02–2.30 0.040 1.71 1.11–2.64 0.014
CC 5 4 1.07 0.39–2.88 0.900 1.52 0.54–4.24 0.429
CG+CC 44 33 1.46 0.99–2.14 0.056 1.70 1.14–2.62 0.009
RAD51
(rs1801321 2172G.T)
TT 144 100 1.00 1.00
TG 84 58 1.14 0.82–1.58 0.429 1.03 0.73–1.45 0.879
GG 0 0 N/A N/A
TG+GG 84 58 1.14 0.82–1.58 0.429 1.03 0.73–1.45 0.879
XRCC2
(rs3218384 4234G.C)
GG 137 97 1.00 1.00
GC 78 53 0.77 0.55–1.08 0.125 0.81 0.56–1.17 0.260
CC 13 8 0.63 0.30–1.29 0.202 0.61 0.28–1.35 0.221
GC+CC 91 61 0.75 0.54–1.03 0.075 0.76 0.54–1.09 0.135
XRCC2
(rs3218536 G.A R188H)
GG 205 138 1.00 1.00
AG 20 18 1.44 0.88–2.36 0.144 1.70 1.02–2.85 0.043
AA 0 0 N/A N/A
AG+AA 20 18 1.44 0.88–2.36 0.144 1.70 1.02–2.85 0.043
XRCC3
(rs861539 C.T T241M)
CC 71 46 1.00 1.00
CT 98 73 1.22 0.84–1.77 0.297 1.17 0.79–1.72 0.428
TT 59 39 0.91 0.60–1.40 0.681 0.89 0.57–1.38 0.593
CT+TT 157 112 1.09 0.78–1.54 0.613 1.06 0.74–1.51 0.766
NBN
(rs1805794 E185Q)
CC 109 71 1.00 1.00
CG 98 72 1.04 0.75–1.44 0.832 1.06 0.75–1.51 0.735
GG 20 14 1.06 0.60–1.87 0.850 0.89 0.48–1.65 0.707
CG+GG 118 86 1.08 0.79–1.47 0.653 1.06 0.76–1.49 0.720
*P values were calculated by Cox proportional model using univariate analysis.
{P values were calculated with adjustment for age, sex, smoking status, tumor histology, KPS score, tumor stage, application of chemotherapy and radiation dose.
doi:10.1371/journal.pone.0020055.t002
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receiving radio(chemo)therapy.
Current models of HR-mediated DSB repair suggest that DSBs
are first recognized and bound by the MRE11-RAD50-NBN
(MRN) complex. MRE11 has both endonuclease and exonuclease
activities that are important for DNA end processing, and RAD50
can bind to DNA that may be involved in tethering sister
chromatids, whereas NBN forms the flexible adapter domain of
MRN and provides the MRN complex with its signaling role
through interactions and activation of its downstream proteins that
ultimately activate the RAD51-dependent HR pathway [20].
The RAD51 gene family consists of several proteins that show
DNA-stimulated ATPase activity and plays a central role in the
HR activation. It interacts directly with several repair proteins,
including XRCC2, XRCC3, BRCA1/2, to form a complex
essential for repair of DNA cross-links (especially XRCC2 and
XRCC3), which maintains genomic stability by using the sister
chromatid as a template for precise repair. Previous studies found
some potentially functional SNPs of HR genetic polymorphisms
(e.g., RAD51-135 G.C, 2172G.T, XRCC2 4234G.C, R188H,
XRCC3 T241M and NBN E185Q) to be associated with various
types of cancer risks, including cancers of the lung, breast, ovary,
leukemia and head and neck [21]. Some SNPs also showed a
significant effect on survival outcomes, such as RAD51-135 G.C
in breast cancer [22], XRCC2 R188H in pancreatic cancer [23],
and SNPs of RAD51-135 G.C and XRCC3 T241M in acute
myeloid leukemia [24]. However, most studies performed in
prostate or breast cancer failed to find any significant association
with risk of radiation-induced complications [25,26]. In the
current study, there appeared a significant SNP-survival associa-
tion (XRCC2 R188H) and a marginally significant SNP-RP
association (XRCC3 T241M) in radiation-treated NSCLC patients.
Most importantly, the SNP of the central HR gene, RAD51
2135G.C SNP, was robustly associated with both OS and RP
Figure 1. Overall survival and risk of radiation pneumonitis by selected polymorphisms of DNA double-strand break genes. (A) and
(B), overall survival by RAD51 2135G.C and XRCC2 R188H SNPs; (C) and (D), radiation pneumonitis by RAD51 2135G.C and XRCC3 T241M SNPs. The
P values were obtained from the Cox hazards model with adjustment.
doi:10.1371/journal.pone.0020055.g001
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operating characteristic (ROC) curves analyses, which showed that
RAD51 2135G.C in particular was highly valuable to improve
the predictive power of assessing clinical outcomes (e.g., OS and
RP) of NSCLC patients treated with radiotherapy (data not
shown). Taken together, our results demonstrated the importance
of the HR pathway in response to thoracic radiation and possible
tumor-specific influence from HR genetic polymorphisms.
To date, the functional changes of RAD51, XRCC2, XRCC3 and
NBN caused by the SNPs included in the current study have not
been well studied. Some studies found that the threonine-to-
methionine substitution at codon 241 of the XRCC3 gene (T241M)
was associated with radiosensitivity in non-cancer subjects but did
not cause significant difference in DNA repair capacity between
the variant and wild-type genotypes [27,28], while the glutamine-
to-glutamic acid substitution at codon 185 of NBN gene (E185Q)
may influence the interaction between NBN and BRCA1 proteins
responsible for recognition and repair of aberrant DNA [29,30].
However, the role of arginine-to-histidine substitution at codon
188 of the XRCC2 gene (R188H) is largely unknown. The 2135
G.C SNP, located in the promoter region of the RAD51 gene,
results in the up-regulated gene expression through an increased
Table 3. Univariate and multivariate analyses of different genotypes and RP (grade$1) for NSCLC (N=196).
Genotypes Patient No. Event Crude P* Adjusted P
{
HR 95% CI HR 95% CI
RAD51
(rs1801320 2135G.C)
GG 156 115 1.00 1.00
CG 34 18 0.55 0.34–0.91 0.020 0.50 0.29–0.84 0.009
CC 5 3 0.60 0.15–2.44 0.477 0.80 0.19–3.37 0.764
CG+CC 39 21 0.56 0.35–0.90 0.017 0.52 0.31–0.86 0.010
RAD51
(rs1801321 2172G.T)
TT 125 89 1.00 1.00
TG 71 48 0.82 0.58–1.17 0.279 0. 730 0.50–1.08 0.117
GG 0 0 N/A N/A
TG+GG 71 48 0.82 0.58–1.17 0.279 0. 730 0.50–1.08 0.117
XRCC2
(rs3218384 4234G.C)
GG 120 85 1.00 1.00
GC 66 47 1.03 0.72–1.47 0.870 1.21 0.81–1.80 0.361
CC 10 5 0.86 0.35–2.13 0.748 0.90 0.35–2.32 0. 830
GC+CC 76 52 1.01 0.72–1.43 0.949 1.17 0.79–1.73 0.437
XRCC2
(rs3218536 G.A R188H)
GG 173 126 1.00 1.00
AG 16 8 0.56 0.27–1.14 0.107 0.55 0.25–1.19 0.129
AA 0 0 N/A N/A
AG+AA 16 8 0.56 0.27–1.14 0.107 0.55 0.25–1.19 0.129
XRCC3
(rs861539 C.T T241M)
CC 58 43 1.00 1.00
CT 81 59 0.90 0.61–1.33 0.591 0.92 0.60–1.40 0.690
TT 57 35 0.70 0.45–1.09 0.119 0.63 0.38–1.04 0.069
CT+TT 138 94 0.81 0.57–1.17 0.263 0.80 0.54–1.19 0.271
NBN
(rs1805794 E185Q)
CC 93 68 1.00 1.00
CG 85 57 0.98 0.69–1.39 0.909 1.09 0.75–1.60 0.651
GG 16 11 1.12 0.59–2.13 0.722 1.09 0.54–2.19 0.805
CG+GG 101 68 1.00 0.71–1.40 1.000 1.10 0.76–1.58 0.629
*P values were calculated by Cox proportional model using univariate analysis.
{P values were calculated with adjustment for age, sex, smoking status, tumor histology, KPS score, tumor stage, application of chemotherapy and mean lung dose.
doi:10.1371/journal.pone.0020055.t003
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essential for optimal repair of DSBs, and its expression level was a
single important factor in modifying DSB repair capacity as
reported in previous studies [32,33]. Based on these findings, the
association of the RAD51 2135C allele with a decreased hazard
for RP and a reduced OS can be reasonably explained by an
increased radioresistance due to the anticipated up-regulated
RAD51 expression. Although the functional relevance of XRCC2
R188H with clinical outcomes of NSCLC patients has not been
clarified, it may either result from its effect on the gene functions
or its linkage with other functional SNPs, which need to be
unraveled by additional mechanistic studies.
The relationship among RP, OS and SNPs of NSCLC patients
was complex and could only be explored preliminarily in the
current investigation. Inoue et al. reported severe RP (grade 3–4) to
be an adverse prognostic factor [34], whereas our study showed
Figure 2. Overall survival by selected polymorphisms of DNA double-strand break genes according to the presence or absence of
RP.
doi:10.1371/journal.pone.0020055.g002
Table 4. RAD51 2135G.C and XRCC2 R188H genotypes and OS by RP (N=196).
Genotypes Patient No. Event Crude P* Adjusted P
{
HR 95% CI HR 95% CI
RAD51
(rs1801320 2135G.C)
Absence of RP
GG 41 35 1.00 1.00
CG+CC 18 14 0.93 0.50–1.73 0.817 0.81 0.39–1.68 0.575
Presence of RP
GG 115 73 1.00 1.00
CG+CC 21 18 2.45 1.45–4.14 0.001 3.03 1.69–5.45 ,0.001
XRCC2
(rs3218536 G.A R188H)
Absence of RP
GG 47 38 1.00 1.00
AG 8 7 1.02 0.45–2.29 0.889 1.22 0.51–2.92 0.653
Presence of RP
GG 126 83 1.00 1.00
AG 8 7 1.98 0.92–4.30 0.080 2.67 1.13–6.29 0.025
*P values were calculated by Cox proportional model using the univariate analysis.
{P values were calculated with adjustment for age, sex, smoking status, tumor histology, KPS score, tumor stage, application of chemotherapy and radiation dose.
doi:10.1371/journal.pone.0020055.t004
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decreased OS. This is not contradictory, because our RP group
included a large proportion of patients with mild/moderate RP
(grade 1 and 2), which was not likely to have an impact on
patients’ survival negatively. Furthermore, some other studies also
did not find any association between RP grade and prognosis [35].
In this study, we were much interested in the finding that the
influences of RAD51 2135G.C and XRCC2 R188H on overall
survival were only evident in patients with RP. Several possibilities
may explain these findings. First, irradiation of lung tissues induces
immediate damage through intracellular protein denaturation,
membrane disruption, and alterations of DNA. RP is largely a
consequence of cellular DNA injury that appears in the second
generation of cells [36]. The absence of RP may imply a low
amount of DNA injury, which could result from an efficient DNA
repair, whereas the presence of RP may indicate a high amount of
DNA injury due to a suboptimal DNA repair. Therefore, it can be
speculated that if the host cells have optimal DNA repair capacity,
the activity of the entire HR machinery is less likely to be
influenced by a single HR genetic polymorphism. On the
contrary, if the DNA repair capacity is suboptimal, the subsequent
changes in gene expression or activity resulting from functional
SNPs may pose a substantial influence on the whole HR
machinery. Second, RP per se is an inflammatory response to
ionizing radiation, which triggers a large network of signaling
events, including transient activation of pro-survival pathways
such as the epidermal growth factor receptor (EGFR) pathway
[37], and upregulation of a variety of cytokines, such as tumor
necrosis factor alpha (TNF-a), interleukins, and transforming
growth factor beta (TGF-b) [38,39,40]. Although many of these
inflammatory responses are harmful to normal tissue, they confer a
survival advantage of tumor cells and regulate cellular radiation
response and DNA repair. Hence, the SNP-survival association
could be more pronounced in the presence of RP. Additional
mechanistic studies are needed to test these hypotheses.
Despite these positive findings, our study has some limitations.
First, we were not able to explore the mechanism of how the HR
genetic polymorphisms and RP influence survival outcomes of
lung cancer patients. Secondly, we used a candidate polymor-
phism approach, which allowed us to focus on potentially
functional SNPs reported in the literatures but did not compre-
hensively cover all SNPs in the entire gene. Some important SNPs
may have been missed or the observed association may result from
genetic linkages with other untyped SNPs. These warrant
additional investigation of the tagging SNPs that may help find
the underlying disease-causing variants in future studies. Thirdly,
our sample size is still not large enough to perform stratified
analyses for identifying the high-risk subgroups.
In summary, we found that HR genetic polymorphisms,
particularly RAD51 2135G.C, may influence the overall survival
and risk of radiation pneumonitis in NSCLC patients treated with
definitive radio(chemo)therapy. Future prospective studies with
large sample sizes and better study designs are required to confirm
our findings.
Supporting Information
Figure S1 PCR-based restriction analysis. Genotypes of
the RAD51, XRCC2, XRCC3 and NBN SNPs were shown on
agarose electrophoresis.
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